Topical Finasteride for Androgenetic Alopecia — Reducing Systemic Side Effects

Topical finasteride delivers DHT-suppression at the scalp with substantially lower systemic exposure than the oral 1 mg tablet. Published trials show comparable hair density outcomes to oral finasteride with lower reported sexual side effects. NexLife's hair health program uses a compounded topical finasteride + minoxidil formulation.

Why topical over oral finasteride

Oral finasteride 1 mg suppresses serum DHT by ~70%, which produces strong scalp DHT suppression but also drives systemic side effects (sexual side effects in 2–4% of men). Topical finasteride delivers DHT suppression at the scalp with substantially lower serum DHT suppression and a more favorable side-effect profile.

Evidence

Published trials of topical finasteride (Piraccini et al., JEADV 2022; Hajheydari et al., J Cutan Med Surg 2009; Mazzarella et al.) show comparable hair density outcomes to oral finasteride with lower reported sexual side effects. Most formulations are 0.25% solution or gel applied once daily.

Compounded combination — finasteride + minoxidil

The modern compounded approach combines topical finasteride 0.25% with topical minoxidil 5% in a single daily application, capturing the additive efficacy of DHT inhibition plus vasodilator/anagen-prolonging action.

NexLife approach

NexLife's hair health program uses this compounded combination at $49/mo under physician oversight by Medical Director Adam Kennah, M.D.. Patients with significant androgenetic alopecia who plateau on this combination may step up to oral dutasteride.

Sources

• Piraccini et al., Topical finasteride — JEADV 2022
• Hajheydari et al., Topical finasteride trial — J Cutan Med Surg 2009
• Caserini et al., Topical finasteride 0.25% — Skin Pharmacol Physiol 2014